116 related articles for article (PubMed ID: 30731250)
1. Glucagon-Like Peptide-1 Is a Marker of Systemic Inflammation in Patients Treated with High-Dose Chemotherapy and Autologous Stem Cell Transplantation.
Ebbesen MS; Kissow H; Hartmann B; Grell K; Gørløv JS; Kielsen K; Holst JJ; Müller K
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1085-1091. PubMed ID: 30731250
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-Like Peptide-1 Is Associated With Systemic Inflammation in Pediatric Patients Treated With Hematopoietic Stem Cell Transplantation.
Ebbesen M; Kissow H; Hartmann B; Kielsen K; Sørensen K; Stinson SE; Frithioff-Bøjsøe C; Esmann Fonvig C; Holm JC; Hansen T; Holst JJ; Müller KG
Front Immunol; 2021; 12():793588. PubMed ID: 34956226
[TBL] [Abstract][Full Text] [Related]
3. Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation.
Chakraborty R; Muchtar E; Kumar SK; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Bone Marrow Transplant; 2018 Feb; 53(2):155-161. PubMed ID: 29131152
[TBL] [Abstract][Full Text] [Related]
4. Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.
Sun L; Li S; El-Jawahri A; Armand P; Dey BR; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; McAfee SL; Spitzer TR; Chen YB; DeFilipp Z
Oncologist; 2018 May; 23(5):624-630. PubMed ID: 29284757
[TBL] [Abstract][Full Text] [Related]
5. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
6. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
Olivieri J; Mosna F; Pelosini M; Fama A; Rattotti S; Giannoccaro M; Carli G; Tisi MC; Ferrero S; Sgherza N; Mazzone AM; Marino D; Calimeri T; Loseto G; Saraceni F; Tomei G; Sica S; Perali G; Codeluppi K; Billio A; Olivieri A; Orciuolo E; Matera R; Stefani PM; Borghero C; Ghione P; Cascavilla N; Lanza F; Chiusolo P; Finotto S; Federici I; Gherlinzoni F; Centurioni R; Fanin R; Zaja F;
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1814-1822. PubMed ID: 29857196
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis.
Kissow H; Hartmann B; Holst JJ; Poulsen SS
Gut; 2013 Dec; 62(12):1724-33. PubMed ID: 23086829
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal Toxicity, Systemic Inflammation, and Liver Biochemistry in Allogeneic Hematopoietic Stem Cell Transplantation.
Jordan K; Pontoppidan P; Uhlving HH; Kielsen K; Burrin DG; Weischendorff S; Christensen IJ; Jørgensen MH; Heilmann C; Sengeløv H; Müller K
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1170-1176. PubMed ID: 28344059
[TBL] [Abstract][Full Text] [Related]
10. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies.
Naumann-Winter F; Greb A; Borchmann P; Bohlius J; Engert A; Schnell R
Cochrane Database Syst Rev; 2012 Oct; 10():CD004626. PubMed ID: 23076906
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
12. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma.
Kim Y; Kim SJ; Cheong JW; Cho H; Chung H; Lee JY; Jang JE; Min YH; Kim JS
Hematol Oncol; 2017 Dec; 35(4):465-471. PubMed ID: 27440113
[TBL] [Abstract][Full Text] [Related]
14. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon.
Jeppesen PB; Hartmann B; Thulesen J; Hansen BS; Holst JJ; Poulsen SS; Mortensen PB
Gut; 2000 Sep; 47(3):370-6. PubMed ID: 10940274
[TBL] [Abstract][Full Text] [Related]
15. High-dose chemotherapy with autologous stem cell transplantation in relapsed or refractory germ cell tumours: outcomes and prognostic variables in a case series of 17 patients.
Lewin J; Dickinson M; Voskoboynik M; Collins M; Ritchie D; Toner G
Intern Med J; 2014 Aug; 44(8):771-8. PubMed ID: 24893627
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
[TBL] [Abstract][Full Text] [Related]
17. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation.
Berro M; Arbelbide JA; Rivas MM; Basquiera AL; Ferini G; Vitriu A; Foncuberta C; Fernandez Escobar N; Requejo A; Milovic V; Yantorno S; Szelagoswki M; Martinez Rolon J; Bentolila G; Garcia JJ; Garcia P; Caeiro G; Castro M; Jaimovich G; Palmer S; Trucco JI; Bet LA; Shaw BE; Kusminsky GD
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1646-1650. PubMed ID: 28669923
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma.
Huang LW; Bacon W; Cirrincione C; Peterson B; Long G; Rizzieri D; Sullivan KM; Corbet K; Horwitz M; Chao N; Gasparetto C; Tuchman SA
Hematol Oncol; 2017 Dec; 35(4):752-759. PubMed ID: 28105753
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom.
Kassam S; Chernucha E; O'Neill A; Hemmaway C; Cummins T; Montoto S; Lennard A; Adams G; Linton K; McKay P; Davies D; Rowntree C; Easdale S; Eyre TA; Marcus R; Cwynarski K; Fox CP
Bone Marrow Transplant; 2017 Sep; 52(9):1268-1272. PubMed ID: 28581466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]